SIBO and Skin: How Small Intestinal Bacterial Overgrowth Drives Rosacea and Other Skin Conditions

SIBO and Skin: How Small Intestinal Bacterial Overgrowth Drives Rosacea and Other Skin Conditions

This is the fourth and final post in our series on the gut–skin axis. We have covered the science of why gut health determines skin health, how to recognise the warning signs that your gut is driving your skin condition, and what a layered, evidence-based approach to resolving it actually looks like. In this post, we zoom in on SIBO and skin conditions. SIBO is one of the most clinically significant — and most consistently under-diagnosed — contributors to gut-driven skin disease.

SIBO occupies a unique position in the gut–skin axis literature. For most gut-driven skin conditions, the evidence base is built on associations — dysbiosis correlates with disease severity, gut microbiome profiles differ between patients and healthy controls, and interventions that restore gut health tend to improve skin outcomes. All of that is compelling, but it is largely observational.

Fortunately, SIBO is different. For rosacea in particular, we have something considerably more powerful: randomised clinical trial data demonstrating that eradicating SIBO produces near-complete regression of skin lesions. That is a level of causal evidence that is rare in this field — and it has significant clinical implications for anyone with rosacea, perioral dermatitis, or other chronic facial inflammatory skin conditions who has never been asked about their gut.

What Is SIBO?

Small intestinal bacterial overgrowth occurs when bacteria that normally reside in the large intestine colonise the small intestine in excessive numbers. The small intestine is not designed to host large bacterial populations. It is the primary site of nutrient absorption, and its relative sterility under normal conditions is maintained by stomach acid, bile, digestive enzymes, and the migrating motor complex (MMC) — a wave-like muscular contraction that sweeps the small intestine clean between meals.

When any of these protective mechanisms are impaired, bacteria proliferate in the small intestine, where they do not belong. Common triggers include reduced stomach acid from long-term proton pump inhibitor use, sluggish gut motility, structural abnormalities, immune dysfunction, or prior gut infections.[1]

A closely related condition, intestinal methanogen overgrowth (IMO), involves the overgrowth not of bacteria but of methane-producing archaea — primarily Methanobrevibacter smithii — in the small intestine. IMO tends to present with constipation rather than the diarrhoea or loose stools more typical of hydrogen-dominant SIBO, and is clinically important to distinguish because the treatment approach differs.

The consequences of SIBO extend well beyond the gut. Bacterial overgrowth in the small intestine produces excess lipopolysaccharides (LPS – found in the outer membrane of certain bacteria), depletes fat-soluble vitamins (vitamins A, D, E, K), interferes with carbohydrate fermentation, damages the gut lining, and disrupts tight junction integrity — producing the increased intestinal permeability that allows bacterial metabolites to enter systemic circulation.[2]

A 2022 study published in Nutrients confirmed that SIBO creates a pro-inflammatory environment in the small intestine, with patients showing significantly elevated IL-1β levels compared to those without SIBO — confirming that the inflammatory effects of SIBO reach beyond the gut.[3]

Once systemic LPS circulates, it activates Toll-like receptor 4 (TLR4) on immune cells throughout the body, triggering inflammation. This systemic inflammatory signalling — originating in the small intestine, circulating through the bloodstream — creates the conditions for cutaneous inflammation in the skin.

Is Your Gut Causing Skin Issues?

Shop our gut tests

SIBO and Rosacea: The Strongest Evidence in the Gut–Skin Axis

No gut–skin association in the research literature is supported by stronger clinical evidence than the connection between SIBO and rosacea. It is also one of the most actionable.

The Landmark Trial

The foundational study was published in Clinical Gastroenterology and Hepatology (Parodi et al., 2008). Researchers enrolled 11 rosacea patients and 60 healthy age- and sex-matched controls, subjecting all participants to lactulose and glucose breath tests to detect SIBO.[4]

SIBO was identified in 52 of 113 rosacea patients (46%) compared with just 3 of 60 healthy controls (5%) — a prevalence difference of nearly tenfold.

SIBO-positive patients were then randomised to receive either rifaximin (a non-absorbed, gut-selective antibiotic) or placebo. In the rifaximin group, SIBO was eradicated in 28 of 32 patients. Of those with successful eradication, 20 of 28 (71%) experienced complete clearance of their rosacea skin lesions, and a further 6 of 28 (21%) showed marked improvement. In the placebo group, 18 of 20 patients remained unchanged and 2 worsened.

Patients in the placebo group were subsequently switched to rifaximin. Of these, 17 of 20 had SIBO eradicated — and 15 of those 17 experienced complete rosacea resolution.

Importantly, in patients treated with rifaximin who did not have SIBO, the antibiotic produced no meaningful skin improvement. This confirms that the effect was specifically mediated by SIBO eradication, not by a general antibiotic effect on the skin microbiome.

The 3-Year Follow-Up

Perhaps the most clinically significant finding came from the trial’s follow-up, published in the Journal of the American Academy of Dermatology (2016). Researchers tracked patients for three years after SIBO eradication.[5]

The outcomes were striking: 96% of patients who achieved remission remained symptom-free at 9 months, and 65% remained in remission after 3 years. For a condition characterised by frequent relapses with traditional topical and antibiotic therapy, these outcomes are clinically exceptional. Addressing the underlying gut problem produced durable skin remission — not suppression.

The Meta-Analysis Evidence

A 2025 meta-analysis pooled data from six studies including 581 rosacea patients and 220 controls.[6] The overall prevalence of SIBO in rosacea patients was 35.8%, compared to 9.4% in controls. Rosacea patients were 3.5 times more likely to have SIBO than healthy controls. Rifaximin treatment produced significant improvement or remission in 57.9% of patients overall, rising to 85.7% in those with confirmed successful eradication.

A 2026 review in Dermatology Reports concluded that reductions in gut microbial taxa including Lactobacillus, Prevotella copri, Lachnospiraceae, and Faecalibacterium prausnitzii may initiate the inflammation underlying rosacea — and that SIBO, by driving systemic LPS and cytokine production, is one of the key mechanisms through which gut dysbiosis produces facial erythema, papules, and pustules.[7]

How Does Gut Bacteria Cause Facial Inflammation?

To summarise, SIBO bacteria produce excess LPS, which enters systemic circulation through the compromised gut barrier. Circulating LPS activates TLR4 on immune cells, triggering elevated TNF-α — a cytokine that has been directly shown to promote abnormal innate immune responses in rosacea, including the aberrant activation of cathelicidin antimicrobial peptides and kallikrein serine proteases that drive vasodilation, erythema, and tissue remodelling in rosacea skin.[4,5]

SIBO also disrupts bile acid metabolism, impairs the absorption of fat-soluble vitamins including vitamin D and vitamin A (both important for skin barrier function and immune regulation), and suppresses short-chain fatty acid (SCFA) production. This creates both a nutritional deficit and an inflammatory environment that perpetuates skin inflammation.

Are There Other Gut Conditions Associated With Rosacea?

The SIBO finding sits within a wider pattern of gut-rosacea associations that has become increasingly well-documented in the research literature.

Helicobacter Pylori

H. pylori infection is significantly more prevalent in rosacea patients than in controls. A 2024 meta-analysis published in PLOS ONE pooled data from 23 case-control and cross-sectional studies encompassing 51,054 rosacea patients and over 4.7 million controls, finding significantly higher H. pylori prevalence in rosacea .[8]

H. pylori triggers pro-inflammatory cytokines including TNF-α, IL-1β, and IL-8, and generates reactive oxygen species (oxidative stress) that promote abnormal vascular responses and immune dysregulation in the skin. Eradication of H. pylori has been associated with rosacea improvement in clinical studies.[9]

H. pylori is detectable within Healthpath’s Ultimate Gut Health Test, making comprehensive stool testing a natural first step before breath testing in patients with rosacea.

Inflammatory Bowel Disease

Rosacea and IBD share common inflammatory pathways. A 2023 meta-analysis in Dermatology and Therapy pooled eight studies and found rosacea prevalence nearly twice as high in IBD patients compared to controls.[10] Both Crohn’s disease and ulcerative colitis were independently associated with elevated rosacea risk, suggesting shared immune pathways rather than a simple co-occurrence.

A 2025 review in Biomolecules concluded that dysbiosis, SIBO, H. pylori infection, and innate immune dysregulation all contribute to rosacea pathophysiology, and that the gut microbiome’s involvement is now sufficiently established to warrant clinical consideration in rosacea management.[11]

Perioral Dermatitis and the Gut Connection

Perioral dermatitis (POD) — the eruption of small papules and pustules around the mouth, nose, and sometimes eyes — is one of the conditions seen most frequently alongside gut symptoms in clinical practice, and one where the clinical pattern strongly suggests a gut-driven component.

It is important to be clear: the formal evidence base linking SIBO or gut dysbiosis directly to perioral dermatitis is limited. The condition’s pathophysiology remains incompletely characterised in the research literature, and most published treatment studies focus on topical and systemic antibiotics, with little investigation of gut-directed approaches.[12] The SIBO evidence for perioral dermatitis is not analogous to that for rosacea.

That said, there are several reasons why the gut warrants serious clinical consideration in POD.

Perioral dermatitis sits within the rosacea spectrum in many classification frameworks, and some researchers describe it as a variant of rosacea with a perioral distribution. Given the strength of the SIBO–rosacea association, and given that rosacea and POD share immune and inflammatory mechanisms — both involving Toll-like receptor 2 activation, abnormal cathelicidin responses, and mast cell activity — it is certainly possible that the same gut drivers relevant to rosacea are operating in POD.

In clinical settings, patients with perioral dermatitis who also carry gut warning signs — food-triggered flares, chronic bloating, altered bowel habits, histamine reactivity, and multiple food sensitivities — represent a group where a gut assessment is clearly warranted.

The fact that tetracyclines and metronidazole are among the most effective conventional treatments for perioral dermatitis is also worth noting. These antibiotics alter gut microbial composition, and their skin benefits may partly reflect gut-mediated effects, not just direct antimicrobial action at the skin surface. This hypothesis has not been tested in clinical trials but is consistent with the SIBO–rosacea mechanism.

Where a patient presents with perioral dermatitis alongside digestive symptoms — particularly bloating, post-meal discomfort, or a history of gut infections — SIBO breath testing represents a clinically justified and potentially high-yield investigation.

What Other Skin Conditions Are Connected TO SIBO?

Acne Vulgaris

The gut–acne connection is well established, as explored in earlier posts in this series. SIBO’s specific contribution to acne is less directly evidenced than its role in rosacea. The strongest data comes from the observation that acne patients show consistently altered gut microbial profiles — reduced Bifidobacterium, Lactobacillus, and SCFA-producing species, alongside increased Proteobacteria — and that interventions reducing systemic LPS and gut-derived inflammation produce measurable acne improvements.

Research published in Microorganisms (Sivamani et al., 2023) demonstrated that specific gut bacteria directly correlate with acne lesion counts: Clostridium sp. correlated with inflammatory lesion counts, while other taxa correlated with non-inflammatory lesions — confirming the specificity of gut–acne microbial connections.[13]

Whether SIBO is an independent driver of acne is not established by the same quality of evidence as in rosacea. What is clear is that acne patients presenting alongside digestive symptoms consistent with SIBO — post-meal bloating, early satiety, or altered motility — deserve gut assessment rather than indefinite cycles of topical or oral antibiotic treatment.

It is also worth noting that repeated antibiotic courses for acne are themselves a significant cause of dysbiosis and gut barrier disruption. Long-term antibiotic therapy for acne may, over time, worsen the gut dysbiosis that is contributing to the skin condition in the first place.

Psoriasis, Eczema, and Urticaria

The primary gut drivers in these conditions are the broader dysbiosis and gut permeability mechanisms explored throughout this series. SIBO is not as specifically implicated as it is in rosacea. However, because SIBO produces systemic LPS, elevates inflammatory cytokines, and disrupts the gut barrier, it will worsen any gut-driven skin condition where it coexists. In patients with psoriasis, eczema, or chronic urticaria who also have significant digestive symptoms, SIBO is worth investigating as a potential contributing factor.

How Is SIBO Diagnosed?

The standard clinical tool for SIBO diagnosis is the hydrogen and methane breath test. Patients consume a substrate — typically lactulose or glucose — and breath hydrogen and methane concentrations are measured at regular intervals over two to three hours. Because human cells do not produce hydrogen or methane, detectable rises in these gases indicate fermentation by bacteria in the small intestine.

Hydrogen-positive tests indicate bacterial fermentation (SIBO). Methane-positive tests indicate the presence of methane-producing archaea (IMO). Both can coexist

Our SIBO breath test measures both hydrogen and methane, providing a clinically complete picture. The test is conducted at home and returned by post, making it accessible regardless of where you are in the UK.

What Happens After a Positive SIBO Test?

A positive SIBO or IMO breath test opens a treatment pathway that is fundamentally different from standard dermatological management — and, based on the rosacea evidence, potentially far more effective for patients whose skin condition is gut-driven.

Antimicrobial Treatment

Rifaximin is a non-absorbed, gut-selective antibiotic with a strong evidence base for SIBO eradication. Because it acts locally in the gut without significant systemic absorption, it does not carry the same risks of systemic dysbiosis as conventional broad-spectrum antibiotics. It requires a prescription and is typically used at 1,200–1,600 mg per day for 10–14 days, sometimes in combination with neomycin for methane-dominant presentations.

Where pharmaceutical antibiotics are not preferred or accessible, certain herbal antimicrobial protocols — including combinations of berberine, allicin, and oregano oil — have been shown in clinical studies to produce SIBO eradication rates comparable to rifaximin.[14] A 2024 open-label study published in Nutrients assessed a botanical protocol in patients with breath-test-confirmed SIBO and found improvements in both gut markers and facial erythema, directly connecting SIBO eradication to skin outcomes through a non-pharmaceutical approach.[14]

Post-Eradication Gut Restoration

Eradication alone is not sufficient. SIBO recurs in a significant proportion of patients if the underlying factors that allowed it to develop — impaired gut motility, low stomach acid, reduced SCFA-producing bacteria, a compromised mucosal layer — are not addressed. This is where the layered gut health approach from the previous post in this series becomes essential.

Post-eradication, the priorities are as follows.

Motility support. SIBO recurs when the migrating motor complex is impaired. Prokinetic agents — ranging from low-dose naltrexone and pharmaceutical prokinetics to herbal options such as ginger, artichoke leaf extract, and 5-HTP — support MMC function and reduce relapse risk.

Gut barrier restoration. Following antimicrobial treatment, L-glutamine, sodium butyrate, and zinc provide the nutritional substrate for epithelial repair and tight junction restoration.

Microbial reseeding. Once the antimicrobial phase is complete, targeted probiotic supplementation — particularly Lactobacillus and Bifidobacterium strains with documented evidence in gut barrier restoration — helps re-establish a healthy microbiome that is resistant to recolonisation by overgrowth organisms.

Dietary support. A Mediterranean dietary pattern, rich in diverse plant foods and prebiotic fibre, provides the ongoing ecological conditions for a healthy, diverse microbiome. Some practitioners recommend an elemental diet or low-fermentation diet during the active SIBO eradication phase to reduce fermentable substrate — though dietary specifics should be guided by the severity of symptoms and the individual’s response.

The Bottom Line: Should You Be Tested for SIBO?

SIBO is significantly more prevalent in rosacea patients than in healthy controls — approximately 3.5 times more likely. Eradicating it produces complete or near-complete regression of rosacea skin lesions in the majority of successfully treated patients, with remission maintained in the majority for at least three years. This is among the most compelling causal evidence anywhere in the gut–skin axis literature.

For patients with rosacea, perioral dermatitis, or other chronic facial inflammatory skin conditions who also experience digestive symptoms — bloating, post-meal discomfort, altered bowel habits, or symptoms consistent with IBS — SIBO breath testing is a genuinely high-yield clinical investigation. It is non-invasive, accessible, and, if positive, opens a treatment pathway that may support more durable outcomes than topical or conventional systemic approaches alone.

The gut was always part of the story. For patients with rosacea in particular, it may be most of it.

---

References

1. Manfredini M, Barbieri M, Milandri M, Longo C. Probiotics and diet in rosacea: current evidence and future perspectives. Biomolecules. 2025;15:411. doi:10.3390/biom15030411
2. Jimenez-Sanchez M, Celiberto LS, Yang H, Sham HP, Vallance BA. The gut-skin axis: a bi-directional, microbiota-driven relationship with therapeutic potential. Gut Microbes. 2025;17(1):2473524. doi:10.1080/19490976.2025.2473524
3. Saffouri GB, et al. Small intestine bacterial overgrowth can form an indigenous proinflammatory environment in the duodenum. Nutrients. 2022. doi:10.3390/nu14091984
4. Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol. 2008;6(7):759–764. doi:10.1016/j.cgh.2008.02.054
5. Drago F, De Col E, Agnoletti AF, et al. The role of small intestinal bacterial overgrowth in rosacea: a 3-year follow-up. J Am Acad Dermatol. 2016;75(3):e113–e115. doi:10.1016/j.jaad.2016.01.024
6. Bogatova IV, et al. SIBO and rosacea: meta-analysis of prevalence and rifaximin treatment outcomes. Ter Arkh. 2025. doi:10.26442/00403660.2025.01.202978
7. Acuña C, et al. An overview of small intestinal bacterial overgrowth and gut microbiota in patients with rosacea. Dermatol Rep. 2026;6(1):9. doi:10.3390/dermatolrep6010009
8. Gao Y, Yang XJ, Zhu Y, Yang M, Gu F. Association between rosacea and Helicobacter pylori infection: a meta-analysis. PLOS ONE. 2024;19(4):e0301703. doi:10.1371/journal.pone.0301703
9. Association between the treatment of rosacea and eradication of Helicobacter pylori infection. J Cosmet Dermatol. 2023. doi:10.1111/jocd.15701
10. Jun YK, Yu DA, Han YM, et al. The relationship between rosacea and inflammatory bowel disease: a systematic review and meta-analysis. Dermatol Ther (Heidelb). 2023;13(7):1465–1475. doi:10.1007/s13555-023-00964-6
11. Manfredini M, Barbieri M, Milandri M, Longo C. Probiotics and diet in rosacea: current evidence and future perspectives. Biomolecules. 2025;15:411. doi:10.3390/biom15030411
12. Gray NA, Tod B, Rohwer A, et al. Pharmacological interventions for periorificial (perioral) dermatitis in children and adults: a systematic review. J Eur Acad Dermatol Venereol. 2022;36(3):380–390. doi:10.1111/jdv.17817
13. Sivamani RK, Maloh J, Nong Y. Correlating the gut microbiota and circulating hormones with acne lesion counts and skin biophysical features. Microorganisms. 2023;11(8):2049. doi:10.3390/microorganisms11082049
14. Weinstock LB, et al. An oral botanical supplement improves small intestinal bacterial overgrowth (SIBO) and facial redness: results of an open-label clinical study. Nutrients. 2024. doi:10.3390/nu16183149